{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:11:55Z","timestamp":1791357115559,"version":"4.3.1"},"reference-count":22,"publisher":"EDITORA SCIENTIFIC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Bras. Psiquiatr."],"published-print":{"date-parts":[[2003,10]]},"abstract":"<jats:p>OBJETIVE: The present study aimed to analyze 219 notifications of suspected adverse reactions (AR) produced by psychoactive medicaments (ARPM), notified by Brazilian psychiatrists, during a 3-month period (April 1999 up to September 2001). METHOD: A notifying card for adverse reactions possibly produced by psychoactive medications was quarterly sent to all psychiatrists affiliated to the Brazilian Association of Psychiatry. Once each notification, dully filled in, was received, the possible adverse reaction was analyzed in order to verify the causality RESULTS: The psychiatrists classified as severe 50 of the ARPMs; 150 others were not considered as severe. Among the severe ones there were 3 deaths, 12 life-threatening reactions, 26 ARPMs required or prolonged hospitalization and 9 notifications described temporary disability of the patients. Among the medications, antidepressants ranked first with 122 ARPMs being notified, followed by neuroleptics (46 ARPMs) and antiepiletic medicaments (25 ARPMs). The three main organs and systems affected by the ARs were the Central Nervous System with 102 ARs, skin and mucosa with 44 and gastrointestinal with 21 ARPMs. CONCLUSION: Considering causality, i.e., the association between the medication and the described AR, 24 cases were considered as Definite (with positive dechallenge and rechallenge, i.e., withdrawal and reintroduction of the medication) and 134 other ARPMs were classified as Probable (only dechallenge positive; only with medication withdrawal; rechallenge was not performed).<\/jats:p>","DOI":"10.1590\/s1516-44462003000400004","type":"journal-article","created":{"date-parts":[[2005,4,26]],"date-time":"2005-04-26T16:17:49Z","timestamp":1114532269000},"page":"200-205","source":"Crossref","is-referenced-by-count":7,"title":["The pharmacovigilance of psychoactive medications in Brazil"],"prefix":"10.47626","volume":"25","author":[{"given":"Elisaldo Luiz de Ara\u00fajo","family":"Carlini","sequence":"first","affiliation":[{"name":"Federal University of S\u00e3o Paulo; Federal University of S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange Aparecida","family":"Nappo","sequence":"additional","affiliation":[{"name":"Federal University of S\u00e3o Paulo; Federal University of S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27448","reference":[{"key":"ref1","first-page":"9","article-title":"Selective serotonin reuptake inhibitors","volume":"26","year":"2000","journal-title":"Curr Probl Pharmacovigil"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/00004714-199910000-00005","article-title":"Precision and comparability of adverse events rates of newer antidepressants","volume":"19","author":"Vida S","year":"1999","journal-title":"J Clin Psychopharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0271-0749","issn-type":"print"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1055\/s-2002-31515","article-title":"Paroxetine associated hepatotoxicity: a report of 3 cases and a review of the literature","volume":"35","author":"Azaz-Livshits T","year":"2002","journal-title":"Pharmacopsychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0031-7098","issn-type":"print"},{"issue":"87","key":"ref4","article-title":"Pramipexole: sudden onset of sleep","year":"1999","journal-title":"Information Exchange System: Alert"},{"key":"ref5","first-page":"836","article-title":"Punding on L-Dopa","volume":"14","author":"Fernandez HH","year":"1999","journal-title":"Mov Disord","ISSN":"https:\/\/id.crossref.org\/issn\/0855-3185","issn-type":"print"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00004714-199906000-00002","article-title":"Extrapiramidal syndromes in neuroleptic-treated patients: prevalence, risk factors and association with tardive dyskinesia","volume":"19","author":"Muscettola G","year":"1999","journal-title":"J Clin Psychopharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0271-0749","issn-type":"print"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00004714-199910000-00016","article-title":"Neuroleptic malignant syndrome after the initiation of olanzapine","volume":"19","author":"Levenson JL","year":"1999","journal-title":"J Clin Psychopharmacology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1600-0404.1983.tb01537.x","article-title":"Hepatic toxicity of antiepileptic drugs: a review","volume":"68","author":"Gram L","year":"1983","journal-title":"Acta Neurol Scand","ISSN":"https:\/\/id.crossref.org\/issn\/0001-6314","issn-type":"print"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.1996.tb00161.x","article-title":"Psychotic and severe behavioral reactions with vigabatrin: a review","volume":"93","author":"Ferrie CD","year":"1996","journal-title":"Acta Neurol Scand","ISSN":"https:\/\/id.crossref.org\/issn\/0001-6314","issn-type":"print"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1360-0443.1991.tb01831.x","article-title":"Benzodiazepine problems","volume":"86","author":"Lader M","year":"1991","journal-title":"Br J Addict","ISSN":"https:\/\/id.crossref.org\/issn\/0952-0481","issn-type":"print"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(98)04087-2","article-title":"Association of road-traffic accidents with benzodiazepine use","volume":"352","author":"Barbone F","year":"1998","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1176\/appi.ajp.158.11.1774","article-title":"Antipsychotic drugs: prolonged QTc interval, Torsade de Pointes, and sudden death","volume":"158","author":"Glassman AH","year":"2001","journal-title":"Am J Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/(SICI)1099-1557(199611)5:6<393::AID-PDS235>3.0.CO;2-H","article-title":"US Adverse drug reaction surveillance 1984-1994","volume":"5","author":"Faich GA","year":"1996","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0895-4356(97)00219-9","article-title":"Proportion of hospital deaths associated with adverse events","volume":"50","author":"Garcia-Martin M","year":"1997","journal-title":"J Clin Epidemiol","ISSN":"https:\/\/id.crossref.org\/issn\/0895-4356","issn-type":"print"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jama.1997.03540280039031","article-title":"Adverse drug events in hospitalized patients","volume":"277","author":"Classen DC","year":"1997","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cpt1977213247","article-title":"Toward the operational identification of adverse drug reactions","volume":"21","author":"Karch FE","year":"1997","journal-title":"Clin Pharmacol Ther","ISSN":"https:\/\/id.crossref.org\/issn\/0009-9236","issn-type":"print"},{"key":"ref17","series-title":"Detecting adverse drug reactions: Pharmacovigilance in the Netherlands","author":"Meyboom RHB","year":"1998"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1001\/jama.1990.03440130073028","article-title":"Physician reporting of adverse drug reactions","volume":"263","author":"Scott HD","year":"1990","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"ref19","series-title":"Reporting adverse reactions: Definitions of terms and criteria for their use","author":"Bankowski Z","year":"1999"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(05)77665-0","article-title":"Causality assessment of adverse effects: when is rechallenge ethically acceptable ?","volume":"354","author":"Wan Po A","year":"1999","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/bmj.284.6311.249","article-title":"Validity of anecdotal reports of suspected adverse drug reactions: the problem of false alarms","volume":"284","author":"Venning GR","year":"1982","journal-title":"BMJ","ISSN":"https:\/\/id.crossref.org\/issn\/0959-8138","issn-type":"print"},{"key":"ref22","series-title":"Detecting Adverse Drug Reactions: Pharmacovigilance in the Netherlands","volume-title":"Principles of signal detection in pharmacovigilance","author":"Meyboom RHB","year":"1998"}],"container-title":["Revista Brasileira de Psiquiatria"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/rbp\/v25n4\/a04v25n4.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T16:11:10Z","timestamp":1654531870000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1516-44462003000400004&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,10]]}},"alternative-id":["S1516-44462003000400004"],"URL":"https:\/\/doi.org\/10.1590\/s1516-44462003000400004","relation":{},"ISSN":["1516-4446"],"issn-type":[{"value":"1516-4446","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10]]}}}